RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target

Bio-Techne Corporation

Bio-Techne Corporation

TECH

0.00

RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ: TECH) with a Outperform and announces $62 price target.